Light-Based Rhythm Control: Opsin Optogenetics as a Potential Alternative to Pacemakers and Ablation in Pediatric Cardiac Electrophysiology — A Narrative Review

1. Introduction: Opsin Biology, Gene Delivery, and Light-Delivery Platforms

1.1. Opsin Structure and Functional Classes

Opsins are seven-transmembrane, alpha-helical proteins that bind the chromophore retinal to form a light-sensitive pigment — the same molecular scaffold that underlies vision in the vertebrate retina.[1] In neuroscience, and more recently in cardiac electrophysiology, microbial (type I) opsins have been repurposed as optogenetic actuators: genetically encoded, light-gated ion channels or pumps that convert a light pulse into a defined change in transmembrane current.[2] Three functional classes are relevant to cardiac applications. Excitatory channelrhodopsins (ChR2 and its engineered variants — CatCh, CoChR, CheRiff, ReaChR, ChRmine) conduct depolarizing cation currents, principally Na⁺ and Ca²⁺, upon illumination and are used to pace, resynchronize, or block conduction. Inhibitory opsins — halorhodopsins, light-driven proton pumps such as archaerhodopsin (ArchT), and anion channelrhodopsins such as ACR2 and GtACR1 — hyperpolarize the membrane through chloride influx or proton efflux and can silence excitability or terminate arrhythmia through a mechanistically distinct route. A third, less frequently used class of G-protein-coupled opsins modulates intracellular signaling cascades over a slower timescale rather than gating an ionic current directly.[3] This three-part toolkit — fast depolarization, fast hyperpolarization, and slow signaling modulation — is what allows a single underlying technology to address pacing, mapping, and defibrillation alike.

1.2. Gene Delivery: Viral Vectors and the Move Toward Non-Viral Platforms

Translating an opsin from a construct into a functioning cardiomyocyte requires two discrete steps: delivery, the introduction of the genetic material into the cell, and expression, the cell’s own synthesis of the light-sensitive protein from that template.[2] Adeno-associated virus — specifically the cardiotropic serotype AAV9 — has been the workhorse vector in essentially every cardiac optogenetics study to date, whether administered by direct myocardial injection, regional “gene painting,” or a single systemic intravenous injection. AAV9’s popularity reflects a genuinely favorable profile: low pathogenicity, broad cardiotropism, and the capacity for durable, non-integrating transgene expression in the post-mitotic cardiomyocyte. It is not, however, without limitations.[4] Pre-existing neutralizing antibodies, present in a substantial fraction of the general population from prior natural AAV exposure, can inactivate the vector before it reaches the myocardium, and escalating the viral dose to overcome this raises the risk of a pathological innate or adaptive immune response. These constraints have motivated early-stage work on non-viral alternatives — liposomal carriers, engineered non-viral capsids, and inorganic nanoparticles — as a route to transgene delivery without the immunogenicity ceiling that viral vectors impose, although none of these platforms has yet been validated for cardiac opsin delivery at the scale AAV9 has achieved.[5]

1.3. Light-Delivery Platforms

Once expressed, an opsin must be illuminated above an activation threshold, expressed as light power density (mW/mm²), that depends on the specific opsin and its expression level; for wild-type ChR2, triggering an action potential typically requires 1–5 mW/mm².[6] Three broad delivery strategies have been used experimentally.

Optical fibers remain the standard for ex vivo and acute in vivo work. Fiber core diameters of 50–200 µm (a total implant cross-section of a few hundred micrometers once cladding is included) can be positioned against the epicardial surface, most often in a Langendorff-perfused, isolated heart preparation that removes neuronal and hormonal feedback and stabilizes the tissue for reproducible illumination.[6]

LED- and photodiode-based systems extend this principle toward chronic use. Implantable micro-LEDs, held in place by 3D-scaffolded integumentary membranes alongside sensors and other electronics, or implanted directly within the tissue, permit microprocessor-controlled illumination at a programmed rate and intensity.[6] Bioabsorbable implantable microelectronics and optical waveguides have been developed in parallel, allowing short-term illumination for optogenetic interrogation or photodynamic ablation without a second surgical procedure to remove the device.[6] Related optoelectronic principles already underlie clinically deployed technology: photoplethysmography pairs an LED source with a photodiode detector to derive SpO₂, blood pressure, and heart-rate data from pulsatile blood-volume changes, and stretchable, ultrathin organic LED/photodiode “skins” have been demonstrated for continuous perioperative pulse oximetry, integrating red and green polymer LEDs with organic photodiodes in a 3-mm-thick, 60%-strain-tolerant laminate — illustrating the direction in which implantable cardiac optoelectronics is heading.[7,8]

Wearable and fully implantable devices represent the long-term engineering target. Such devices must be thin, flexible, and biocompatible enough for conformal contact with a beating heart, and encapsulated against water and ionic infiltration while remaining mechanically compliant — a trade-off in which soft polymers offer superior flexibility and inorganic layers offer superior barrier properties.[9] Choi and colleagues demonstrated a fully implantable, bioresorbable cardiac pacemaker encapsulated in poly(lactic-co-glycolic acid) (PLGA), a polyester that hydrolyzes in vivo to glycolic and lactic acid and is cleared by normal metabolic pathways, showing that a device’s biodegradation timescale can in principle be engineered to match the required therapeutic window.[10] Gutruf and colleagues went further, developing a fully implantable, battery-free, wireless multisite pacemaker — powered by magnetic resonant coupling rather than an onboard battery — capable of both electrical and optogenetic (ChR2-mediated) pacing in small-animal hearts, with in vivo capture demonstrated over multiple days in freely moving rats. By removing the physical battery and lead-wire architecture entirely, this design addresses precisely the mechanical burden — wire fatigue, battery volume, and generator size — that dominates the pediatric device-longevity problem discussed in Section 4.[11] A related closed-loop concept couples a stretch-sensitive strain sensor to a self-adaptive LED array so that illumination intensity is automatically titrated to the mechanical signature of diastole and systole; in an ArchT-expressing animal model of ventricular tachycardia, this reduced tachyarrhythmic cycle length back toward baseline within roughly eight minutes of activation.[12]

2. Real Applications in Cardiac EP Research

2.1. Optogenetic Pacing (the “Biological Pacemaker”)

Cardiac optogenetics offers, at least in principle, excellent cell selectivity, high spatiotemporal resolution, low energy consumption, programmable pace control, and painless actuation, although substantial further work is needed on opsin choice, light-intensity parameters, and pulse timing before any of this translates into a device.[12] In representative rodent protocols, cardiac pacing is achieved with brief (~20 ms) 470 nm blue-light pulses at a frequency slightly above the animal’s resting heart rate, while red light (617 nm) is used to induce transient arrest or bradycardia by continuous or intermittent illumination.[12] Mechanistically, optogenetic pacing substitutes a genetically delivered, light-gated ion channel for the electrode-tissue interface of a conventional pacemaker: illumination of ChR2- or ReaChR-expressing myocardium triggers the same voltage-gated cascade that underlies a normal action potential, so the resulting depolarization wavefront and capture threshold behave analogously to electrical pacing.[13] Gutruf and colleagues’ wireless multisite pacemaker, described above, is the clearest embodiment of this principle to date, achieving chronic optical capture in rats without the mechanical burden of wires and batteries.[11]

2.2. Optical Mapping and Arrhythmia-Mechanism Studies

Optical mapping is a fluorescence-based technique that visualizes the electrophysiological behavior of multicellular cardiac preparations — from cellular monolayers to whole hearts — at a spatiotemporal resolution unmatched by point-contact electrodes. Voltage- and/or Ca²⁺-sensitive fluorescent indicators are loaded into the preparation and illuminated (typically by LEDs); the resulting fluorescence is captured by high-speed cameras to reconstruct action potential morphology, calcium-transient dynamics, and conduction patterns across the tissue.[13,14] Combined with optogenetic actuation, this produces “all-optical” electrophysiology, in which light alone both controls and reads out cardiac electrical activity, with no metal electrode in contact with the tissue.[14,15] Optical mapping has become a central research tool for cardiac electrophysiology and arrhythmogenesis, contributing insights ranging from the genetic basis of atrial fibrillation to the chamber-specific pharmacology of antiarrhythmic agents.[13] Closed-loop implementations extend this further: a strain-sensing membrane detects the mechanical signature of an abnormal rhythm (for example, a ventricular tachycardia-range beat rate) and triggers a self-adaptive LED array to deliver ArchT-mediated hyperpolarizing illumination, automatically modulating light intensity across the cardiac cycle until cycle length normalizes.[12] Such systems illustrate the field’s trajectory from open-loop, pre-programmed illumination toward adaptive, on-demand devices capable of detecting and correcting conduction disorders in real time, using multi-site patterned illumination to counteract arrhythmia at its origin.[16]

2.3. Optical Defibrillation and Arrhythmia Termination

Optogenetic arrhythmia termination has been developed as an alternative to conventional electrical cardioversion and defibrillation, which, despite established clinical efficacy, is associated with pain, myocardial and chest-wall injury, and the substantial psychological morbidity of ICD shocks.[17,18] Optical defibrillation uses targeted light pulses, rather than high-voltage electrical shocks, to terminate reentrant arrhythmia via light-sensitive proteins introduced into cardiomyocytes.

Mechanisms. Two principal, non-mutually-exclusive mechanisms have been proposed for how sustained illumination terminates reentrant arrhythmia (spiral waves/rotors). Functional (transmural) conduction block occurs when continuous illumination depolarizes a large area of tissue simultaneously, creating a block through which the existing reentrant wavelet cannot propagate, so the rotor is extinguished; this depends on sustained depolarization prolonging the refractory period and inactivating voltage-gated Na⁺ channels across the myocardial wall.[17,19] Excitable-gap filling, by contrast, is analogous to antitachycardia pacing: a light-induced depolarizing wavefront is timed to collide with and annihilate the arrhythmic wavefront in the small, dynamic region of tissue between the head and tail of the reentrant circuit. This mechanism requires precise knowledge of the excitable gap’s location and is considered less reliable, particularly in atrial fibrillation, where the gap is small and spatially inhomogeneous.[19] Human tissue-model work using hiPSC-derived cell sheets and engineered heart tissue has favored the functional conduction-block mechanism, since shorter or lower-density illumination — conditions that would be expected to favor excitable-gap capture — were consistently less effective at terminating arrhythmia, the opposite of what the wave-collision hypothesis predicts.[20]

Landmark preclinical experiments. The evidence base spans in vitro monolayers, ex vivo and in vivo whole-heart preparations, hiPSC-derived human tissue models, and a small number of computational and large-animal studies (summarized in Table 1).

In vitro monolayers and tissue slices. Bingen and colleagues demonstrated that diffuse blue-light illumination reliably terminated spiral-wave reentry in CatCh-expressing neonatal rat atrial cardiomyocyte monolayers at very low irradiance (38 µW/mm², 500 ms pulse), establishing feasibility at the cellular level.[21] Subsequent work from the same laboratory group, using transverse ventricular tissue slices, showed that a spatially localized, reversible conduction block could terminate anatomical reentry by either wave collision or extinction depending on the transmurality of illumination, refining the mechanistic picture from planar monolayers to three-dimensional tissue.[22] Majumder and colleagues further demonstrated real-time spatiotemporal control over spiral-wave dynamics using patterned, closed-loop illumination in an excitable cardiac monolayer system.[23]

Human hiPSC-derived tissue models. Gruber and colleagues established a family of light-controllable human cardiac tissue models by coupling CoChR- or CheRiff-expressing HEK293 cells with hiPSC-derived cardiomyocytes, producing two-dimensional cell sheets and three-dimensional engineered heart tissue (EHT) coupled through native gap junctions.[24,25] In the 2D cell-sheet model, diffuse continuous illumination reliably terminated spiral-wave reentry, with an optimal illumination-duration window of 100–200 ms producing maximal termination across illumination-grid densities from 25–100% of the field; both too-short (≤50 ms, insufficient to establish a conduction block) and too-long (≥400 ms, which could reinitiate a new peripheral reentrant circuit at areas of local heterogeneity) durations reduced efficacy, defining a U-shaped “defibrillation time window.”[24] In the 3D EHT model, burst-pacing-induced macro-reentry was reliably terminated by diffuse illumination, with cumulative termination plateauing at 80% for a 50 ms pulse.[24] In a separate hiPSC model of short-QT syndrome, dynamically prolonging action-potential duration/wavelength ahead of a premature stimulus using patterned, tracking illumination prevented spiral-wave induction in a dose-dependent manner, from 55% protection at a 1 mm wavelength increase to complete (100%) protection at 2.6 mm — notably without needing to fully restore the wavelength of healthy control tissue.[25] Because these are human-cell-derived engineered tissues rather than animal models, they are argued to be more directly translatable to human electrophysiology than rodent preparations, although the oncogenic potential of the HEK293 coculture component is noted as a barrier to clinical (as opposed to research) use of this specific approach.[24,25]

Whole-heart and in vivo optical defibrillation. Bruegmann and colleagues provided the landmark in vivo proof of concept: epicardial illumination terminated ventricular arrhythmia in both ChR2-transgenic mice and wild-type mice after AAV-based ChR2 gene transfer, with efficacy extending to an ex vivo infarct (LAD-ligation) model of diseased myocardium.[17] The same study modeled optogenetic defibrillation computationally in a clinically validated in silico human infarct-VT platform, finding that red — rather than blue — light was necessary for effective transmural termination in human-scale tissue because of light-penetration limits.[17] Vogt and colleagues had earlier shown that a single systemic (non-surgical) intravenous AAV9 injection could achieve sufficient ChR2 expression to overcome the electrical “sink” of non-transduced tissue and support reliable whole-heart optical pacing in otherwise non-transgenic mice, establishing the delivery paradigm subsequently used for defibrillation.[26] Nyns and colleagues delivered the red-shifted opsin ReaChR systemically via cardiotropic AAV in adult Wistar rats, achieving ~93% ventricular transduction; a single local epicardial pulse (470 nm, 1000 ms, 2.97 mW/mm², illuminating only ~125 mm² of ventricular surface) terminated 97% of monomorphic and 57% of polymorphic ventricular tachycardia, versus 0% in unilluminated controls, with termination preceded by significant action-potential-duration (APD) prolongation that was causally linked to efficacy by pharmacological APD manipulation.[27] The authors explicitly flagged that termination succeeded with illumination of only a small fraction of the epicardial surface — suggesting local rather than systemic vector delivery could suffice therapeutically — while also noting that heart size may affect translatability, an early statement of the large-animal translational gap discussed in Section 5.[27] Durability has been examined directly: in rats that received a single AAV-ChR2 injection in infancy, optical capture and defibrillation remained effective a full year later, including after monocrotaline-induced myocardial fibrosis was superimposed to model a chronically remodeled substrate — an important data point for the persistence of viral gene delivery and of defibrillation efficacy in diseased, rather than only acutely healthy, myocardium.[28] The ventricular defibrillation paradigm has since been extended to atrial fibrillation, with epicardial ChR2 illumination terminating AF in a connexin-40-mutated, diazoxide-sensitized mouse model,[29] and to a fully automated, closed-chest hybrid bioelectronic system that detects AF and triggers local, implanted-LED optogenetic termination with high detection accuracy and termination success and no evidence of local hyperthermia.[30,31] A chronic pressure-overload (transverse aortic constriction) rat heart-failure model with an implanted LED for local ReaChR-based cardioversion further moved the field toward a genuine disease substrate and an implantable-device paradigm, with Monte Carlo modeling used explicitly to optimize light penetration.[32]

Patterned illumination and translational barriers. Patterned (rather than global/diffuse) light delivery — using digital micromirror devices or liquid-crystal spatial light modulators to target only the mechanistically critical tissue region, or multi-site circumferential micro-LED/ECG arrays that combine local and global illumination modes — can achieve termination at substantially lower total energy cost than global illumination, echoing the illumination-grid-density findings from the hiPSC tissue models above.[15,16] A comprehensive review of the field’s technical and translational barriers highlights: variable transfection rates with a consistent chamber discrepancy (atrial AAV transduction is reliably lower than ventricular); cytotoxicity associated with high-level lentiviral ChR2 expression in cultured neonatal cardiomyocytes, mechanism unclear but implicating calcium overload; and the continued need for improved methods of in vivo light and gene delivery, wireless device control, and bio-integrated flexible electronics before clinical translation becomes feasible.[17,33] A detailed computational study comparing red-shifted opsins (ChRmine, bReaChES, CsChrimson) in simulated human ventricular cardiomyocytes found that ChRmine could be triggered at power densities two to three orders of magnitude lower than ChR2(H134R) (as low as ~0.7 µW/mm² for a 100 ms pulse at 585 nm), enabling safe excitation to a simulated depth of up to roughly 10 mm from the pericardial surface at longer wavelengths — directly addressing the light-penetration and multi-site-delivery barrier and pointing toward energy-efficient, minimally invasive human devices.[34]

Noninvasive transthoracic approaches. Two recent studies point toward a genuinely noninvasive delivery route. Using right atrial AAV2/9 “gene painting” to achieve transmural ReaChR expression with minimal extra-atrial spread, a combined rodent and human-tissue-modeling study achieved transthoracic AF termination and modeled light transmittance through human atrial tissue to support translatability.[35] A more recent study using a transgenic mouse line with stable, uniform cardiac-restricted ReaChR expression (avoiding the AAV chamber-discrepancy problem noted above) applied broad-area transthoracic LED illumination rather than a focal fiber/LED spot; Monte Carlo simulation showed this achieves roughly two orders of magnitude greater fluence at cardiac depth (~3 mm) than focal illumination at the same skin-surface irradiance, enabling effective transthoracic optical pacing at irradiances over 100-fold lower than earlier transthoracic work and well within accepted skin-exposure safety limits.[36] This removes one of the field’s most direct translational barriers — safe, noninvasive light delivery through the chest wall — although, as with all work summarized here, no large-animal or human transthoracic data yet exist.[36]

Neuromodulatory and computational bridges. The only published large-animal cardiac optogenetics study to date used AAV2/9-mediated ArchT delivery to cardiac sympathetic neurons of the left stellate ganglion in beagle dogs, suppressing myocardial ischemia-induced ventricular arrhythmia via optogenetic silencing of the ganglion rather than direct myocardial actuation — a neuromodulatory rather than myocardial-targeting approach that offers an alternative translational route with a potentially lower gene-delivery burden.[37] Patient-specific computational models reconstructed from cardiac imaging have also been used to compare distributed versus targeted illumination strategies for atrial arrhythmia termination, generally finding that spatially targeted, sufficiently long pulses outperform diffuse illumination in simulation.[38]

Summary of the field’s trajectory. Taken together, the literature on optical defibrillation and arrhythmia termination has progressed from primary-cell monolayer cultures, through isolated whole-heart preparations with local epicardial illumination, to in vivo mouse and rat hearts with systemic AAV delivery, to chronic and diseased-substrate models, to hiPSC-derived human 2D/3D tissue models with defined mechanistic “defibrillation time-windows,” to patterned and energy-optimized illumination strategies, and most recently to fully noninvasive transthoracic approaches and computational human-scale extrapolation with red-shifted opsins.[36] Rodent in vivo and ex vivo whole-heart models still dominate the literature; zebrafish larvae have been used for whole-organism optical pacing. No large-animal (pig, dog, or sheep) myocardial-targeting study and no human data exist in the published literature, which remains the field’s principal translational gap.[36,37]

Table 1. Representative preclinical model systems in cardiac optical defibrillation research.

Model system	Representative work	Primary use
hiPSC-CM single cells (healthy, LQTS, SQTS lines; ChR2 or ACR2)	Gruber et al.[25]	AP-duration modulation, EAD suppression, patch-clamp/optical characterization
hiPSC-CM cell sheet + CoChR-HEK293 coculture	Gruber et al.[24,25]	Optogenetic pacing, resynchronization, reentry induction and termination
3D engineered heart tissue (EHT; hiPSC-CM + CheRiff-HEK293 in collagen hydrogel)	Gruber et al.[24]	Mechanical/contractile-force studies during pacing and defibrillation
Mouse in vivo/ex vivo whole heart (ChR2-transgenic or AAV-transduced)	Bruegmann et al.[17]; Vogt et al.[26]	Ventricular pacing and defibrillation, mechanistic studies
Rat in vivo/ex vivo whole heart (systemic AAV-ReaChR)	Nyns et al.[27]; Li et al.[28]	VT/AF termination, chronic durability, fibrotic-substrate testing
Mouse AF model (Cx40-mutant)	Bruegmann et al.[29]	Atrial defibrillation mechanism
Closed-chest hybrid bioelectronic system	Nyns et al.[30,31]	Automated AF detection and light-triggered termination
Chronic heart-failure rat (TAC) with implanted LED	Nyns et al.[32]	Disease-substrate cardioversion, light-penetration modeling
Transgenic ReaChR mouse, transthoracic illumination	Amaral et al.[36]	Noninvasive pacing/arrhythmia induction, hemodynamic consequences
Canine stellate ganglion (ArchT, neuromodulatory)	Yu et al.[37]	Only published large-animal cardiac optogenetics study to date
Patient-specific computational atrial models	Boyle et al.[38]	Targeted vs. distributed illumination strategy comparison

Table 1. Representative preclinical model systems in cardiac optical defibrillation research.

Model system	Representative work	Primary use
hiPSC-CM single cells (healthy, LQTS, SQTS lines; ChR2 or ACR2)	Gruber et al.[25]	AP-duration modulation, EAD suppression, patch-clamp/optical characterization
hiPSC-CM cell sheet + CoChR-HEK293 coculture	Gruber et al.[24,25]	Optogenetic pacing, resynchronization, reentry induction and termination
3D engineered heart tissue (EHT; hiPSC-CM + CheRiff-HEK293 in collagen hydrogel)	Gruber et al.[24]	Mechanical/contractile-force studies during pacing and defibrillation
Mouse in vivo/ex vivo whole heart (ChR2-transgenic or AAV-transduced)	Bruegmann et al.[17]; Vogt et al.[26]	Ventricular pacing and defibrillation, mechanistic studies
Rat in vivo/ex vivo whole heart (systemic AAV-ReaChR)	Nyns et al.[27]; Li et al.[28]	VT/AF termination, chronic durability, fibrotic-substrate testing
Mouse AF model (Cx40-mutant)	Bruegmann et al.[29]	Atrial defibrillation mechanism
Closed-chest hybrid bioelectronic system	Nyns et al.[30,31]	Automated AF detection and light-triggered termination
Chronic heart-failure rat (TAC) with implanted LED	Nyns et al.[32]	Disease-substrate cardioversion, light-penetration modeling
Transgenic ReaChR mouse, transthoracic illumination	Amaral et al.[36]	Noninvasive pacing/arrhythmia induction, hemodynamic consequences
Canine stellate ganglion (ArchT, neuromodulatory)	Yu et al.[37]	Only published large-animal cardiac optogenetics study to date
Patient-specific computational atrial models	Boyle et al.[38]	Targeted vs. distributed illumination strategy comparison

3. Advantages of Opsins over Classic EP Treatments (Medications and Ablation)

3.1. Spatial and Temporal Precision Versus Pharmacologic Non-Selectivity

Antiarrhythmic pharmacotherapy is constrained by a fundamental mismatch between the scale at which arrhythmias arise and the scale at which drugs act. A reentrant circuit, an ectopic focus, or an accessory pathway occupies a discrete, often millimeter-scale volume of myocardium, yet a systemically administered sodium-, potassium-, or calcium-channel blocker distributes throughout the entire cardiovascular system and beyond. Because the ion channels targeted by classic antiarrhythmics — Nav1.5, hERG, L-type calcium channels — are not unique to the arrhythmogenic substrate and are also expressed across atrial, ventricular, nodal, His-Purkinje, and in some cases neuronal and skeletal-muscle tissue, therapeutic and proarrhythmic effects are inseparably linked. A dose sufficient to suppress the target arrhythmia frequently also slows conduction or prolongs repolarization in healthy myocardium, producing the well-documented paradox in which antiarrhythmic agents can themselves precipitate life-threatening arrhythmia — most notably QT prolongation and torsades de pointes with class IA/III agents, or 1:1-conducted atrial flutter with class IC agents.

Optogenetic actuation addresses this problem at two levels pharmacology cannot access simultaneously. Spatially, opsin expression can be restricted anatomically by the delivery method (targeted catheter-based or epicardial injection, regional AAV serotype tropism) and restricted cellularly by promoter choice (cardiac troponin, myosin, or connexin promoters for cardiomyocyte-restricted expression, with conduction-system-specific promoters under active investigation); illumination is then patterned in space using fiber-optic arrays, flexible LED meshes, or projected light fields, so that only the doubly selected population — genetically competent and physically illuminated — is actuated. This two-factor (genetic × optical) gating has no pharmacologic analogue: a drug cannot be “aimed” at a scar border zone or a single pulmonary vein ostium.[45] Temporally, channelrhodopsins and related opsins activate and deactivate on a millisecond timescale, permitting light delivery phase-locked to the cardiac cycle — restricted to the vulnerable window of the action potential, timed to a specific point in a reentrant circuit, or gated by a closed-loop sensor that fires only during a detected arrhythmic episode. Antiarrhythmic drugs, by contrast, are present continuously once absorbed; their pharmacokinetics impose a therapeutic exposure that persists for hours regardless of whether an arrhythmic episode is actually occurring, and this continuous “always-on” channel blockade is precisely what generates cumulative off-target risk. Optogenetic tools can in principle operate on-demand: light delivered only during an episode, computationally triggered by real-time rhythm analysis, with the tissue electrophysiologically undisturbed between episodes.[39] Brief, appropriately timed optogenetic hyperpolarization has already been shown to terminate ventricular arrhythmia in murine hearts, illustrating that a defibrillation-equivalent effect can be achieved with a stimulus confined to a few seconds rather than a sustained pharmacologic exposure.[39]

This dual precision is particularly consequential in children. Pediatric patients have a narrower therapeutic index for most antiarrhythmics because of immature hepatic and renal clearance, rapidly changing body composition and weight-based dosing that must be recalculated as the child grows, and a disproportionate burden of extracardiac side effects — the growth, thyroid, pulmonary, and neurodevelopmental effects of agents such as amiodarone are of particular concern with long-term pediatric exposure. CHD further complicates pharmacokinetics through altered hepatic and renal blood flow, polypharmacy, and structurally abnormal chambers in which drug effect and arrhythmia substrate do not map predictably onto one another. A modality that could, in principle, confine its electrophysiological effect to the anatomically and cellularly relevant substrate — without systemic exposure, without hepatic/renal clearance requirements, and without a maintenance dosing schedule that must be re-titrated as the child grows — would remove an entire axis of risk that is intrinsic, rather than incidental, to pharmacologic therapy.

3.2. Non-Thermal, Potentially Reversible Tissue Interaction Versus Ablation Scar

Catheter ablation, whether radiofrequency- or cryo-based, achieves its therapeutic effect by deliberately destroying the arrhythmogenic tissue: radiofrequency energy generates resistive heating that denatures cellular proteins and causes coagulation necrosis, while cryoablation freezes tissue to produce a comparable, if better-demarcated, zone of cell death. In both cases the mechanism of cure is also the long-term liability — a fixed, non-conducting fibrotic scar replaces functioning myocardium. In adults with structurally normal hearts, this trade-off is usually favorable and durable. In children, several features of the ablation-scar model are more problematic.

The growth mismatch. A lesion created in a pediatric heart is geometrically fixed at the moment of ablation, but the heart around it continues to grow for years. The relationship between a scar and the chamber, valve annulus, or conduction pathway it was intended to interrupt can therefore change over time in ways that are not present when ablation is performed in an already fully grown adult heart. This is one reason pediatric EP series have flagged the absence of long-term, into-adulthood follow-up data as an open concern, alongside possible late atrioventricular block, coronary injury adjacent to the lesion, and cumulative radiation exposure from fluoroscopically guided procedures.[40] Pediatric operators have also directly noted lesion growth after ablation in small hearts, prompting extra caution and, in some settings, a preference for cryoablation over radiofrequency energy in vulnerable locations.[41]

Scar as a new arrhythmogenic substrate. Perhaps the more fundamental irony of thermal ablation is that the scar created to cure one arrhythmia can itself become the anatomic substrate for a new one. Heterogeneous conduction around lesion borders, slow zones of viable tissue trapped within scar, and non-transmural lesions that appear acutely successful but recover conduction later are all recognized mechanisms of macroreentrant, scar-related tachyarrhythmia. This phenomenon is best documented in adults with repaired CHD, in whom abnormal anatomy, post-surgical scarring, and associated hemodynamic and systemic factors together establish the dominant substrate for late arrhythmia, with roughly half of patients projected to develop an atrial tachyarrhythmia by 20 years after index repair.[42] A child who undergoes ablation early in life has, by definition, a much longer subsequent interval over which such lesion-related arrhythmia can manifest than an adult ablated later in life — the scar’s arrhythmogenic potential has decades, rather than years, to declare itself. Pediatric anatomic reviews also note that complication rates from thermal ablation are highest specifically in the youngest and smallest patients, reflecting the disproportionate injury a fixed-size lesion inflicts on a disproportionately small heart.[41]

Non-thermal optogenetic actuation. Opsin-based approaches modulate membrane potential by directly gating ion flux through the light-activated protein itself — depolarizing currents via channelrhodopsins, hyperpolarizing currents via anion channelrhodopsins or light-driven pumps such as ArchT — without generating heat, freezing, or any deliberate tissue-injuring energy transfer. The functional effect (local depolarization, hyperpolarization, or conduction block) is achieved and then relaxes when illumination stops, rather than being locked in by necrosis. Because the myocardium is not destroyed, this approach does not, by design, leave behind a fixed anatomic scar that must later be reconciled with a growing heart, nor does it create the heterogeneous conduction borders that seed macroreentry. Experimental optogenetic termination of ventricular arrhythmia has been explicitly framed by investigators as a potentially nondamaging, and in principle pain-free, alternative to conventional defibrillation shocks, precisely because it substitutes a reversible membrane-potential perturbation for tissue injury.[17] Contemporary reviews of cardiac optogenetics more broadly highlight that light-based actuation is contactless and cell-selective, with markedly lower cytotoxicity than chemical or electrical alternatives — a property that stands in direct contrast to a therapy whose entire mechanism of action is localized tissue destruction.[13]

“Reversibility” here operates on two levels that should be kept conceptually distinct. At the level of the acute tissue interaction, the effect is reversible by definition: once illumination ceases, the opsin closes (or the pump stops transporting ions) and the membrane returns to its native resting behavior, with no necrosis to reverse. At the level of the underlying genetic modification, reversibility is a more qualified, forward-looking claim — current viral vectors (chiefly AAV) produce long-term, and in non-dividing cardiomyocytes potentially durable, transgene expression that is not itself easily switched off, though inducible or excisable expression systems are an active area of engineering that could eventually make even the genetic layer conditionally reversible. For a pediatric-facing rationale, the clinically important point is the first one: the tissue-level interaction does not require destroying myocardium to achieve rhythm control, sidestepping the scar-growth mismatch and lesion-related late arrhythmia risk that are intrinsic to thermal ablation performed in a heart that still has years of growth ahead of it.

3.3. Theoretical Scalability to Small and Complex Anatomy

Because optogenetic therapy targets the electrical characteristics of specific cardiomyocytes rather than depending on anatomical catheter access alone, it presents a distinct theoretical advantage over standard catheter-based intervention: in principle, a cell-specific method could be adapted for small hearts or highly complex anatomy — such as CHD — where standard catheter navigation and point-by-point ablation are difficult. This potential is, at present, strictly theoretical. The great majority of the evidence available for any of the applications described in Section 2 comes from animal models and isolated tissue preparations rather than human subjects, and — critically for this review’s stated purpose — none of it comes from a pediatric or congenital anatomical model. All therapeutic uses of opsins for cardiac arrhythmia remain preclinical: in cultured cardiomyocytes, murine models, zebrafish, and a handful of large-animal preparations, research to date has shown effective optical pacing, modulation of cardiac conduction, and termination of experimental arrhythmias — but not, so far, in a model that recapitulates the pediatric or congenital heart.[43,44,45]

4. Limitations of Pacemakers and Ablation Specifically in Pediatric EP

4.1. Anatomic Constraints: TGA, Isomeric Hearts, and Single-Ventricle Physiology

Cardiac optogenetics presents major anatomical and technical challenges for many forms of CHD, despite its theoretical adaptability. Therapeutic efficacy may be limited by structural defects, surgical alterations, cardiac fibrosis, and altered conduction pathways that affect gene delivery, opsin expression, and light penetration alike. These anatomic subgroups should currently be regarded as potential future applications rather than established indications.[43,44]

Transposition of the great arteries (TGA). Because of severe surgical scarring and altered conduction pathways, patients with TGA — particularly after an atrial-switch (Mustard or Senning) or arterial-switch procedure — frequently experience atrial and ventricular arrhythmias. The spatial precision of optogenetic stimulation could theoretically allow selective modulation of arrhythmogenic tissue while sparing surrounding myocardium, but opsin-based rhythm control has not been assessed in any published preclinical model that mimics corrected-TGA architecture; its potential function in this population is entirely unknown.[44,47]

Isomeric heart (heterotaxy syndrome). Cardiac anatomy in left or right atrial isomerism varies enormously, with complex structural anomalies, abnormal or duplicated sinus nodes, and altered atrioventricular conduction pathways. These features present substantial challenges for targeted gene transfer and controlled optical stimulation. Optogenetic arrhythmia therapy has not been studied experimentally in isomeric hearts, and any proposed use rests on theoretical extrapolation alone.

Single-ventricle physiology. Although optogenetics’ cell-specificity could theoretically circumvent some of the constraints that limit conventional catheter placement in single-ventricle anatomy, effective cardiac gene transfer and sufficient light penetration into hypertrophied or fibrotic myocardium remain major unresolved challenges, and successful optogenetic treatment has not been demonstrated in any experimental model of single-ventricle physiology.[43,45]

Post-repair CHD more broadly. Re-entrant arrhythmias associated with scar tissue, prosthetic material, and abnormal conduction pathways commonly occur after surgical correction of CHD. Optogenetic therapy offers a theoretical method for selectively altering these arrhythmogenic substrates without the collateral myocardial damage of thermal ablation, but surgical fibrosis may itself restrict efficacy by impairing both optical penetration and viral vector dissemination. This applicability remains entirely theoretical and has not been examined in clinically representative models of CHD.[43,44]

4.2. Limited Mapping/Ablation Surface Area in Small, Surgically Altered Hearts

Consider what an electrophysiologist is working with in a small CHD heart: a chamber that may be only a fraction of adult size, containing a correspondingly constrained reentry substrate that must be identified and ablated with real precision. In adults, reentry circuits and their protected isthmuses can occupy a proportionally larger area of the atrial or ventricular surface; in pediatric CHD, the available mapping area is considerably more limited. Triedman and colleagues found that entrainment-confirmed regions in intra-atrial reentrant tachycardia after CHD repair involved a median of just 21 cm² (range 2–75 cm²) of atrial tissue, often within chambers already distorted by scar, patch material, or previous atriotomy suture lines.[48] In this setting, even small errors in defining the critical isthmus can substantially change the apparent circuit; the underlying mechanisms of these reentrant tachycardias also vary considerably by the type of prior repair, which itself predicts how difficult localization will be.[49] Successful ablation occurred at a site distant from the presumed protected isthmus in roughly half of Triedman and colleagues’ cases — a striking illustration of how difficult it is to accurately characterize reentry within such constrained anatomy.[48]

The relative size of the catheter compounds this problem. Standard 3.5–4.0 mm ablation tips, and the lesions they produce, are proportionally large when applied to the thinner atrial or ventricular walls of a small pediatric heart, reducing the margin for error and raising real concern about injury to adjacent normal myocardium or conduction tissue, particularly in smaller children.[50] High-density electroanatomic mapping has improved spatial resolution, allowing smaller accessory-pathway insertion sites and reentry circuits to be delineated more precisely and potentially reducing the number of energy applications needed for success. Even so, a recent feasibility study of the RHYTHMIA mapping system found that these systems still require substantially more manual reannotation in patients weighing under 20 kg, particularly around the atrioventricular annulus — so while high-density mapping improves resolution, it reduces rather than eliminates the challenge posed by small cardiac dimensions.[51]

These limitations are amplified further by the complex postoperative anatomy seen in many patients with CHD. In patients following Fontan palliation or atrial-switch (Mustard/Senning) procedures, simply accessing the relevant atrial surface may require transbaffle puncture or a retrograde arterial approach; surgical patches, baffles, and extensive scar further restrict catheter access and complicate localization of the arrhythmogenic substrate.[50] The American Heart Association’s scientific statement on Fontan circulation reports acute ablation success rates of only 54–94% in this population, with early recurrence around 50% for patients with older-style atriopulmonary Fontan connections.[52] More broadly, atrial tachycardia recurrence is more frequent in patients with complex surgical atrial anatomy — including Fontan and atrial-switch patients — than in those with simpler CHD repairs, despite comparable acute procedural success in some series.[53] Consistent with these challenges, the PACES/HRS expert consensus statement strongly supports 3D nonfluoroscopic electroanatomic mapping and recommends that ablation in patients with moderate-to-complex CHD be undertaken specifically by operators with expertise in this population.[54]

These constraints amount to more than a technical footnote; they represent a fundamental limitation of conventional mapping and focal ablation in pediatric EP. Small chamber dimensions leave little room for spatial error, while complex postoperative anatomy can make the critical substrate both hard to reach and hard to define. This combination is also part of what motivates interest in optogenetic approaches: a spatially distributed, non-contact, light-based strategy could, in principle, ease some of the limitations that come with point-by-point mapping and focal thermal ablation in small, anatomically complex hearts. Such applications remain, however, entirely preclinical and theoretical (see Section 5); the relevance of optogenetics here lies not in any established clinical advantage, but in its potential to address limitations that arise directly from the anatomy and scale of the pediatric CHD heart.

4.3. Device-Related Burden: Lead Complications, Growth Mismatch, and Repeated Battery/Generator Changes

Despite rapid advances in cardiac implants, pediatric populations face challenges that separate them from adult counterparts. Device-related complications are common, and the age at implantation, anatomical variation, and frequency of replacement and reoperation all shape outcomes — while remaining difficult to predict, as complications can occur suddenly and unexpectedly.[55] Because children receive implants at a young age, devices are effectively expected to last a lifetime, which current engineering and materials science cannot yet reliably deliver.

ICD lead complications in pediatric populations are relatively common, with lead survival rates of 87% at 10 years, 78% at 15 years, and 69% at 20 years.[56] These complications include lead fracture, insulation failure, venous obstruction, and lead-related tricuspid regurgitation. Because of pediatric anatomy, leads are typically placed with additional slack to accommodate future growth, which increases mechanical stress and can itself precipitate failure; the smaller vasculature of children also makes venous stenosis and obstruction more common, which, if severe, can require lead extraction and makes future reoperations more difficult still.[57]

Growth mismatch between the child and the implanted device is a major obstacle in pediatric cardiac EP and is closely intertwined with the lead complications above. It is compounded by stretching of the implanted lead as the child grows, which can precipitate fracture or dislodgement, and further exacerbated by the high level of physical activity typical of children, which increases the risk of device impairment.[57,58]

Battery changes in pediatric implantable devices are typically required every 5–10 years, though this interval varies with several factors. Children tend to have higher resting heart rates and cardiac demands than adults, which can deplete ICD batteries faster; smaller children require smaller pacemakers, which inherently carry generators with shorter battery lifespans.[59] Newer devices show improved size, programming, and battery life, so many pediatric complications are increasingly driven by the interaction between patient factors and the device rather than by the device in isolation. However, because pediatric patients are implanted decades before the end-of-life expectancy typically reached in an adult population, they accumulate far more device replacements over a lifetime, and each generator change carries its own independent surgical risk.[62]

4.4. Why These Constraints Amount to a Genuine Unmet Need

These device-related burdens converge into a lifelong cascade of interventions that begins in early childhood and compounds over decades. A child receiving an implanted device at a young age can expect multiple generator changes and several lead revisions across the following decades of life, imposing substantial physical and psychological stress that meaningfully affects quality of life.

Current cardiac implantables were designed primarily for adult populations, and their software algorithms, rate-responsive parameters, and device configurations are correspondingly mismatched to pediatric physiology. For example, children experience inappropriate ICD shocks at higher rates than adults because normal physiologic tachycardia is more often misread as ventricular arrhythmia — shocks that carry a heavy psychological toll on young children, in devices that still lack pediatric-specific programming to prevent them.[62]

Similarly, pediatric ablation carries higher procedural risk and a greater likelihood of requiring repeat intervention as the child grows, forcing clinicians toward more conservative and less definitively effective strategies. The absence of pediatric-specific catheter technology and imaging means current tools are, at best, adapted rather than purpose-built for this population. Major gaps also persist in the research base itself: data on very young children remain limited, with many patients lost to long-term follow-up, and the long-term effects of repeated lead extractions on vascular and valvular integrity remain unknown. Clinicians are consequently left to adapt adult technology to a fundamentally different patient population.

Taken together, these limitations highlight a genuine, unmet need in pediatric cardiac EP. Children require therapies that accommodate somatic growth, align with pediatric physiology, minimize cumulative procedural burden, preserve long-term venous access, and reduce device-related complications. Current pacing and ablation technologies do not, on their own, meet these needs, exposing children to repeated interventions that increase lifetime risk. Novel and emerging approaches — leadless pacing, subcutaneous defibrillators, and biological pacing among them — have the potential to overcome some of these limitations by providing more durable, growth-compatible rhythm management with a reduced need for repeated procedures, and it is against this specific unmet need that the theoretical advantages of opsin-based optogenetics, discussed in Section 3, take on their pediatric relevance.

5. Limitations of Opsin-Based Approaches, and Conclusions

The rationale built across Section 3 and Section 4 is, deliberately, a rationale rather than a clinical claim: cardiac optogenetics could in principle address several problems that are specific and severe in pediatric EP, but the technology carries its own substantial, unresolved limitations, several of which are at least as severe in a small, growing patient as the problems it might solve.

5.1. Immunogenicity and Durability of Gene Delivery

Every opsin-based cardiac application reviewed in Section 2 depends on introducing foreign genetic material into cardiomyocytes, almost always via AAV. Pre-existing neutralizing antibodies — common in the general population from prior natural AAV exposure — can block transduction outright, and this problem may be compounded rather than resolved in children, who receive an increasing number of routine childhood vaccinations and viral exposures across the same developmental window in which any opsin-based therapy would need to be delivered and would need to remain durably expressed. Escalating vector dose to overcome neutralization raises the risk of a pathological immune response, and cytotoxicity has been reported with high-level lentiviral ChR2 expression in cultured neonatal cardiomyocytes, through a mechanism that remains incompletely understood but appears to implicate calcium overload and membrane injury.[17,33] Because AAV produces long-term, non-integrating expression in the post-mitotic cardiomyocyte, the genetic modification is not readily “switched off” once delivered — a property that sits uncomfortably alongside a patient population that will, by definition, live with the consequences of that decision for many decades, and for whom no long-term (into-adulthood) safety data of any kind currently exist.

5.2. Light Penetration, Phototoxicity, and Device-Engineering Barriers

Effective optogenetic actuation requires light intensities above an opsin- and expression-level-specific threshold to reach the target tissue, and native ChR2 and its close relatives generally require power densities that would risk skin and tissue phototoxicity if delivered transthoracically through conventional means, necessitating either multi-site intracardiac light delivery or the kind of broad-area, low-irradiance transthoracic strategies and red-shifted, ultra-low-power opsins (such as ChRmine) that have only very recently begun to close this gap experimentally.[34,36] Light penetration is further degraded, specifically, by the fibrotic and hypertrophied myocardium characteristic of repaired or palliated CHD — precisely the substrate identified in Section 4 as most in need of an alternative to conventional ablation — creating a direct tension between the population optogenetics might help most and the population in which it is likely to work least well with current technology.[43,44] On the device-engineering side, a genuinely long-term, biocompatible, chronically implantable light source for a small, growing chest remains unbuilt: existing wearable and implantable optoelectronic platforms have been demonstrated in adult-scale or rodent models, not in a device engineered for the growth trajectory, vascular access constraints, and body-surface area of an infant or young child.[6,9,10,11]

5.3. Absence of Large-Animal and Human Safety Data — and of Any Pediatric-Specific Model

This is, for a pediatric-facing narrative review, the most consequential limitation of all. As summarized in Section 2, the only published large-animal cardiac optogenetics study to date used a neuromodulatory (stellate-ganglion) rather than direct myocardial approach, and no human data of any kind — safety, efficacy, or pharmacokinetic — exist in the peer-reviewed literature.[37] More specifically to this review’s scope: no published preclinical study, in any species, has yet modeled TGA, atrial isomerism, single-ventricle physiology, or any other form of repaired or palliated CHD architecture using opsin-based tools. Every claim of pediatric or congenital relevance made in Section 3 and Section 4 of this review is therefore, by necessity, an extrapolation from adult-anatomy rodent and human-tissue-model data, not a demonstrated finding in a pediatric-relevant model. This gap is not a minor caveat; it is the central reason cardiac optogenetics remains, at present, a research rationale rather than a translational roadmap for pediatric EP.

5.4. Conclusions

Opsin-based optogenetics has, over roughly a decade of preclinical work, matured from single-cell proof-of-concept into a technology capable of pacing, resynchronizing, optically mapping, and defibrillating rodent hearts, and — through hiPSC-derived engineered tissue — of doing so in a genuinely human cellular substrate. Its two defining theoretical strengths — spatial and temporal precision unmatched by pharmacology, and a non-thermal, potentially reversible mechanism of action unmatched by catheter ablation — map with unusual directness onto two of the most persistent problems in pediatric cardiac EP: the narrow therapeutic index and long cumulative drug-exposure window of pediatric pharmacotherapy, and the growth mismatch, lesion-related late arrhythmia risk, and constrained mapping/ablation surface area that make thermal ablation and lifelong device implantation disproportionately burdensome in a small, growing heart. At the same time, the technology’s own translational barriers — viral immunogenicity and expression durability, light penetration through exactly the fibrotic and hypertrophied tissue that characterizes repaired CHD, unresolved chronic-device engineering, and above all a complete absence of large-animal or human safety data, let alone any published pediatric or congenital anatomical model — mean that none of this can currently be offered as more than a rationale for directed future research. The most immediate and tractable next step identified by this review is not a leap to human trials but the first preclinical study of opsin-based rhythm control in an animal model that actually recapitulates pediatric or congenital cardiac anatomy — without which the pediatric relevance of cardiac optogenetics will remain, as it is today, a plausible hypothesis rather than an evidence-based one.